Trial · NCT07908082
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
NCT07908082, Phase 3, Not yet recruiting, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis. Trials, record NCT07908082. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908082
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
- NCT number
- NCT07908082
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Conditions
- Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS), Ishemic and Thrombotic Complications
- Interventions
- Acetyl Salicylic Acid (ASA), Placebo
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment rate defined as the number of participants randomized per center-month. | Through study completion, an average of 18 months | Number of participants randomized per center-month, counting each center from the date it is activated and able to enroll participants until completion of recruitment. |
| Secondary | Study treatment initiation, assessed as the proportion of randomized participants who initiate study treatment. | Up to month 3 following randomization | |
| Secondary | Time to study treatment initiation, assessed as the number of days from randomization to first study treatment administration among randomized participants who initiate treatment. | Up to 30 days following randomization | |
| Secondary | Treatment adherence, assessed using the proportion of days covered. | Up to 12 months following randomization | The proportion of days covered is calculated as the number of days covered by the dispensed study medication divided by the total number of days in the treatment period, multiplied by 100. |
| Secondary | Participant retention, defined as the proportion of randomized participants completing the 12-month follow-up visit. | Up to 12 months following randomization | |
| Secondary | Completeness of follow-up data, assessed as the proportion of randomized participants completing the 12-month visit for whom all clinical outcome data required for the definitive trial are available. | Up to 12 months following randomization | |
| Secondary | Study-drug delivery performance, assessed as the proportion of participants experiencing ≥1 delivery-related delay resulting in delayed treatment initiation or treatment interruption. | Up to 12 months following randomization | |
| Secondary | Barriers for recruitment, assessed by the frequency of reasons for ineligibility. | Through study completion, an average of 18 months | |
| Secondary | Barriers for adherence, assessed by the frequency of reasons for treatment discontinuation. | Through study completion, an average of 18 months | |
| Secondary | Barriers for retention, assessed by the frequency of reasons for withdrawal from the trial. | Through study completion, an average of 18 months |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908082
GET https://conductscience.org/api/trials/v1/NCT07908082/registered